
Europe Medical Cannabis Market Growth, Size, Trends, Demand, Revenue, Share and Future Outlook
Europe Medical Cannabis Market Size- By Species, By Derivative, By Application, By End User, By Route of Administration- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
Published: May-2024 | Report ID: PHAR2408 | Pages: 1 - 153 | Formats*: |
Category : Pharmaceutical |
- Tilray declared in May 2020 that it had obtained GMP certification in accordance with EU regulations, enabling the establishment to produce medical cannabis extracts on-site and export completed medical cannabis products. This facilitated the company's growth.
- Sanity Group GmbH, a division of Sanity Medical, and Telaleaf, a telemedicine platform, signed a partnership in February 2022 to advance telemedicine in cannabis therapy in Germany.


Report Metric | Details |
Market size available for years | 2020-2033 |
Base year considered | 2023 |
Forecast period | 2024-2033 |
Segments covered | By Species, By Derivative, By Application, By End Use, By Route of Administration |
Regions covered | UK, France, Germany, Italy, Spain, Rest of Europe |
Companies Covered | Tilray, Althea Company Pty Ltd (A subsidiary of Althea Group Holdings Limited), Jazz Pharmaceuticals, Inc., EcoGen Biosciences, GRASS & CO., PharmaHemp, Aurora Cannabis Inc., CANOPY GROWTH CORPORATION, CANNARAY, and Sanity Group GmbH among others |
- Healthcare Professionals
- Patients and Caregivers
- Government Regulators and Policymakers
- Medical Cannabis Producers and Distributors
- Pharmaceutical Companies
- Research Institutions and Academia
By Species: |
|
By Derivative: |
|
By Application: |
|
By End Use: |
|
By Route of Administration: |
|
- Europe Medical Cannabis Market Size (FY’2024-FY’2033)
- Overview of Europe Medical Cannabis Market
- Segmentation of Europe Medical Cannabis Market By Species (Indica, Sativa, Hybrid)
- Segmentation of Europe Medical Cannabis Market By Derivative (Cannabidiol Tetrahydrocannabinol Others)
- Segmentation of Europe Medical Cannabis Market By Application (Cancer, Arthritis, Migraine, Epilepsy, Others)
- Segmentation of Europe Medical Cannabis Market By End Use (Pharmaceutical Industry, Research and Development Centers, Others)
- Expansion Analysis of Europe Medical Cannabis Market
- Problems and Obstacles in Europe Medical Cannabis Market
- Competitive Landscape in the Europe Medical Cannabis Market
- Impact of COVID-19 and Demonetization on Europe Medical Cannabis Market
- Details on Current Investment in Europe Medical Cannabis Market
- Competitive Analysis of Europe Medical Cannabis Market
- Prominent Players in the Europe Medical Cannabis Market
- SWOT Analysis of Europe Medical Cannabis Market
- Europe Medical Cannabis Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1.1. Scope of the report1.2. Market segment analysis
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges4.2. COVID-19 Impacts of the Europe Medical Cannabis Market
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6.1. Europe Medical Cannabis Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Medical Cannabis Market
7.1. Europe Medical Cannabis Market Size, Share and Forecast, By Species, 2020-20267.2. Europe Medical Cannabis Market Size, Share and Forecast, By Species, 2027-20337.3. Indica7.4. Sativa7.5. Hybrid
8.1. Europe Medical Cannabis Market Size, Share and Forecast, By Derivative, 2020-20268.2. Europe Medical Cannabis Market Size, Share and Forecast, By Derivative, 2027-20338.3. Cannabidiol (CBD)8.4. Tetrahydrocannabinol (THC)8.5. Others
9.1. Europe Medical Cannabis Market Size, Share and Forecast, By Application, 2020-20269.2. Europe Medical Cannabis Market Size, Share and Forecast, By Application, 2027-20339.3. Cancer9.4. Arthritis9.5. Migraine9.6. Epilepsy9.7. Others
10.1. Europe Medical Cannabis Market Size, Share and Forecast, By End Use, 2020-202610.2. Europe Medical Cannabis Market Size, Share and Forecast, By End Use, 2027-203310.3. Pharmaceutical Industry10.4. Research and Development Centers10.5. Others
11.1. Europe Medical Cannabis Market Size, Share and Forecast, By Route of Administration, 2020-202611.2. Europe Medical Cannabis Market Size, Share and Forecast, By Route of Administration, 2027-203311.3. Oral Solutions and Capsules11.4. Smoking11.5. Vaporizers11.6. Topicals11.7. Others
12.1. Europe Medical Cannabis Market Size and Market Share
13.1. Europe Medical Cannabis Market Size and Market Share By Region (2020-2026)13.2. Europe Medical Cannabis Market Size and Market Share By Region (2027-2033)13.3. France13.4. Germany13.5. Italy13.6. United Kingdom13.7. Rest of Europe
14.1. Althea Company Pty Ltd14.1.1. Company details14.1.2. Financial outlook14.1.3. Product summary14.1.4. Recent developments14.2. Aurora Cannabis Inc.14.2.1. Company details14.2.2. Financial outlook14.2.3. Product summary14.2.4. Recent developments14.3. CANOPY GROWTH CORPORATION14.3.1. Company details14.3.2. Financial outlook14.3.3. Product summary14.3.4. Recent developments14.4. CANNARAY14.4.1. Company details14.4.2. Financial outlook14.4.3. Product summary14.4.4. Recent developments14.5. EcoGen Biosciences14.5.1. Company details14.5.2. Financial outlook14.5.3. Product summary14.5.4. Recent developments14.6. GRASS & CO.14.6.1. Company details14.6.2. Financial outlook14.6.3. Product summary14.6.4. Recent developments14.7. Jazz Pharmaceuticals, Inc.14.7.1. Company details14.7.2. Financial outlook14.7.3. Product summary14.7.4. Recent developments14.8. PharmaHemp14.8.1. Company details14.8.2. Financial outlook14.8.3. Product summary14.8.4. Recent developments14.9. Sanity Group GmbH14.9.1. Company details14.9.2. Financial outlook14.9.3. Product summary14.9.4. Recent developments14.10. Tilray14.10.1. Company details14.10.2. Financial outlook14.10.3. Product summary14.10.4. Recent developments14.11. Others
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment






Related Reports
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.